Additional Paid in Capital in USD of Regen BioPharma Inc from Q3 2013 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
Regen BioPharma Inc quarterly Additional Paid in Capital history and change rate from Q3 2013 to Q2 2025.
  • Regen BioPharma Inc Additional Paid in Capital for the quarter ending 30 Jun 2025 was $15.5M, a 7.25% increase year-over-year.
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Change (%)

Regen BioPharma Inc Quarterly Additional Paid in Capital (USD)

Period Value YoY Chg Change % Date Report Filed
Q2 2025 $15.5M +$1.05M +7.25% 30 Jun 2025 10-Q 11 Aug 2025
Q1 2025 $15.5M +$1.15M +8.02% 31 Mar 2025 10-Q 28 May 2025
Q4 2024 $15.5M +$1.33M +9.45% 31 Dec 2024 10-Q 16 May 2025
Q3 2024 $15.4M +$759K +5.18% 30 Sep 2024 10-Q 11 Aug 2025
Q2 2024 $14.5M +$799K +5.85% 30 Jun 2024 10-Q 13 Aug 2024
Q1 2024 $14.3M +$650K +4.76% 31 Mar 2024 10-Q 24 Apr 2024
Q4 2023 $14.1M +$1.04M +7.97% 31 Dec 2023 10-Q 19 Jan 2024
Q3 2023 $14.6M +$3.06M +26.4% 30 Sep 2023 10-K 13 May 2025
Q2 2023 $13.7M +$2.46M +21.9% 30 Jun 2023 10-Q 25 Jul 2023
Q1 2023 $13.7M +$3.86M +39.5% 31 Mar 2023 10-Q 18 Apr 2023
Q4 2022 $13.1M +$3.37M +34.7% 31 Dec 2022 10-Q 19 Jan 2023
Q3 2022 $11.6M +$2.94M +34% 30 Sep 2022 10-K 20 Nov 2023
Q2 2022 $11.2M +$2.81M +33.5% 30 Jun 2022 10-Q 22 Jul 2022
Q1 2022 $9.79M +$1.46M +17.6% 31 Mar 2022 10-Q 21 Apr 2022
Q4 2021 $9.71M +$1.38M +16.5% 31 Dec 2021 10-Q 20 Jan 2022
Q3 2021 $8.64M +$330K +3.97% 30 Sep 2021 10-K 15 Nov 2022
Q2 2021 $8.39M +$94K +1.13% 30 Jun 2021 10-Q/A 22 Dec 2021
Q1 2021 $8.33M +$32.9K +0.4% 31 Mar 2021 10-Q 18 Aug 2021
Q4 2020 $8.33M +$25K +0.3% 31 Dec 2020 10-Q 13 Aug 2021
Q3 2020 $8.31M +$51.9K +0.63% 30 Sep 2020 10-K 22 Dec 2021
Q2 2020 $8.3M +$57.7K +0.7% 30 Jun 2020 10-Q 05 Aug 2021
Q1 2020 $8.3M +$450K +5.73% 31 Mar 2020 10-Q 05 Aug 2021
Q4 2019 $8.31M +$615K +7.99% 31 Dec 2019 10-Q 05 Aug 2021
Q3 2019 $8.26M +$744K +9.9% 30 Sep 2019 10-Q 05 Aug 2021
Q2 2019 $8.24M +$1.19M +16.8% 30 Jun 2019 10-Q 24 Oct 2019
Q1 2019 $7.85M +$898K +12.9% 31 Mar 2019 10-Q 29 Aug 2019
Q4 2018 $7.69M +$853K +12.5% 31 Dec 2018 10-Q 12 Feb 2019
Q3 2018 $7.52M +$875K +13.2% 30 Sep 2018 10-K 21 Jun 2021
Q2 2018 $7.06M +$464K +7.04% 30 Jun 2018 10-Q 06 Aug 2018
Q1 2018 $6.95M +$434K +6.66% 31 Mar 2018 10-Q 14 May 2018
Q4 2017 $6.84M -$14.9M -68.5% 31 Dec 2017 10-Q 06 Feb 2018
Q3 2017 $6.64M -$12.3M -65% 30 Sep 2017 10-K 27 Dec 2018
Q2 2017 $6.59M -$10M -60.4% 30 Jun 2017 10-Q 07 Aug 2017
Q1 2017 $6.52M -$8.03M -55.2% 31 Mar 2017 10-Q 05 May 2017
Q4 2016 $21.7M +$8.08M +59.3% 31 Dec 2016 10-Q 27 Jan 2017
Q3 2016 $19M +$7.3M +62.6% 30 Sep 2016 10-Q 27 Jan 2017
Q2 2016 $16.6M +$5.42M +48.4% 30 Jun 2016 10-Q 01 Aug 2016
Q1 2016 $14.6M +$4.65M +46.9% 31 Mar 2016 10-Q 29 Apr 2016
Q4 2015 $13.6M +$13.1M +2586% 31 Dec 2015 10-Q 28 Jan 2016
Q3 2015 $11.7M +$11.2M +2304% 30 Sep 2015 10-K 21 Dec 2016
Q2 2015 $11.2M +$10.7M +2211% 30 Jun 2015 10-Q 29 Jul 2015
Q1 2015 $9.91M +$9.42M +1942% 31 Mar 2015 10-Q 07 May 2015
Q4 2014 $508K 31 Dec 2014 10-Q 04 Feb 2015
Q3 2014 $485K +$300K +162% 30 Sep 2014 10-K/A 28 Apr 2017
Q2 2014 $485K 30 Jun 2014 10-Q 07 Aug 2014
Q1 2014 $485K 31 Mar 2014 10-Q 05 May 2014
Q3 2013 $185K 30 Sep 2013 10-K 18 Dec 2014
* An asterisk sign (*) next to the value indicates that the value is likely invalid.